Document Detail


Extracellular ATP and cancer: an overview with special reference to P2 purinergic receptors.
MedLine Citation:
PMID:  18575829     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Purinergic signal transduction mechanisms have been appreciated as a complex intercellular signalling network that plays an important regulatory role in both short- and long-term processes in practically every living cell. One of the most intriguing aspects of the field is the participation of ATP and other purine nucleotides in the determination of cell fate and the way they direct cells towards proliferation, differentiation or apoptosis, thereby possibly taking part in promoting or preventing malignant transformation. In this review, following a very brief introduction to the historical aspects of purinergic signalling and a concise overview of the structure of and signal transduction pathways coupled to P2 purinergic receptors, the current theories concerning the possible ways how extracellular ATP can alter the function of tumour cells and the effectiveness of anticancer therapies are discussed, including pharmacological, nutritional, vasoactive and 'anti-antioxidant' actions of the nucleotide. The effects of ATP on animals inoculated with human tumours and on patients with cancer are looked over next, and then an overview of the literature regarding the expression and presumed functions of P2 purinoceptors on tumour cells in vitro is presented, sorted out according to the relevant special clinical fields. The article is closed by reviewing the latest developments in the diagnostic use of P2 purinergic receptors as tumour markers and prognostic factors, while discussing some of the difficulties and pitfalls of the therapeutic use of ATP analogues.
Authors:
Tamás Deli; László Csernoch
Related Documents :
8041899 - Radiation dose heterogeneity in receptor and antigen mediated boron neutron capture the...
1165439 - Calcitonin production by rat thyroid tumours.
2186789 - Some special skin tumours in the elderly.
10202379 - Dynamics of reactive oxygen intermediate production in human glioma: n-6 essential fatt...
12001989 - Death and anti-death: tumour resistance to apoptosis.
7984519 - Distribution of the vla family of integrins in normal salivary gland and in pleomorphic...
17053809 - Regulation of cell fate in the sensory epithelia of the inner ear.
7319679 - The contribution of a fat cell pool to adipose tissue cellularity.
23879689 - A role for the copper transporter ctr1 in the synergistic interaction between hyperther...
Publication Detail:
Type:  Journal Article; Review     Date:  2008-06-25
Journal Detail:
Title:  Pathology oncology research : POR     Volume:  14     ISSN:  1219-4956     ISO Abbreviation:  Pathol. Oncol. Res.     Publication Date:  2008 Sep 
Date Detail:
Created Date:  2008-09-30     Completed Date:  2009-03-24     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9706087     Medline TA:  Pathol Oncol Res     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  219-31     Citation Subset:  IM    
Affiliation:
Department of Physiology, Research Centre for Molecular Medicine, Medical and Health Science Centre, University of Debrecen, Debrecen, Hungary.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenosine Triphosphate / analogs & derivatives,  pharmacology,  therapeutic use*
Animals
Cell Line, Tumor
Disease Models, Animal
Humans
Neoplasms / diagnosis,  drug therapy*,  metabolism*
Prognosis
Receptors, Purinergic P2 / metabolism*
Signal Transduction / drug effects
Tumor Markers, Biological / metabolism
Chemical
Reg. No./Substance:
0/Receptors, Purinergic P2; 0/Tumor Markers, Biological; 56-65-5/Adenosine Triphosphate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pelvic Endometriosis is Rarely Associated with Ovarian Borderline Tumours, Cytologic and Architectur...
Next Document:  Unusual clinical history of a male infant with edwards syndrome.